Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:28 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
ZN-c3 + Gemcitabine in Pancreatic Cancer
NCT06015659 · Brandon Huffman, MD · PHASE2 · terminated · last registry update 2026-10-27 · Pancreatic cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study stopped early due to reaching the minimum number of DLTs required for halting the study due to toxicity.” | – | Registry record, Brandon Huffman, MD |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against RRM1 in pancreatic cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-04Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Nab-paclitaxel + Gemcitabine (NCT04753879)
- 2026-11-03Also stopped (suspended): National Cancer Institute (NCI), Emavusertib + Gemcitabine Hydrochloride (NCT05685602)
- 2026-10-28Phase 3 first posted: Shanghai Hengrui Pharmaceutical Co., Ltd., HRS -4642 + SHR-1316+ Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection + HRS -4642 + Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection (NCT07900789)
- 2026-10-08Results posted on the registry: Theriva Biologics SL, Nab-paclitaxel + Gemcitabine (NCT05673811)
- 2026-09-08Phase 3 first posted: Revolution Medicines, Inc., daraxonrasib + gemcitabine (NCT07805954)
- 2026-06-02Phase 3 first posted: Revolution Medicines, Inc., Zoldonrasib + Placebo (NCT07621718)
- 2026-05-01Phase 3 first posted: Immuneering Corporation, Atebimetinib + GnP (NCT07562152)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision